University of Maryland Medical Center
Welcome,         Profile    Billing    Logout  
 373 Trials 
577 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Baer, Maria
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT02878785: Decitabine and Talazoparib in Untreated AML and R/R AML

Completed
1/2
25
US
Decitabine, dacogen, talazoparib, BMN673; MDV3800
University of Maryland, Baltimore, Pfizer, Van Andel Research Institute
Acute Myeloid Leukemia
01/20
11/20
HQP1351CU101, NCT04260022: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Recruiting
1
62
US
Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab, Blincyto
Ascentage Pharma Group Inc.
Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
01/24
01/24
NCT04207190: Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Completed
1
24
US
Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Talazoparib, BMN 673, BMN-673, Talazoparib Tosylate, Talzenna
Roswell Park Cancer Institute, Pfizer
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
05/24
06/24
Mehta, Minesh P
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
NCT04466683: Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia

Active, not recruiting
2
37
US, RoW
Low dose radiation 35 cGy, High dose radiation 100 cGy
Ohio State University Comprehensive Cancer Center, Varian Medical Systems
Covid-19, Sars-CoV2, Pneumonia
12/24
12/25
NCT02847559: Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Recruiting
2
27
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Electric Field Therapy, NovoTTF-200A Device, NovoTTF-200A, NovoTTF-200A System, NovoTTFields, NovoTumor Treatment Fields, Optune, Optune Device, Quality-of-Life Assessment, Quality of Life Assessment
Northwestern University, NovoCure Ltd., National Cancer Institute (NCI)
Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
09/26
12/26
Hussain, Arif
DORA, NCT03574571 / 2018-002944-10: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Recruiting
3
450
Europe, Canada, Japan, US, RoW
AAA617, (177Lu) vipivotide tetraxetan
Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
12/27
07/30
LUCIDA, NCT05458544: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

Recruiting
1/2
26
US
[177Lu]Ludotadipep 3.7 GBq
FutureChem
Metastatic Castration-resistant Prostate Cancer
06/25
06/25
PRESERVE-006, NCT05682443: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Recruiting
1/2
144
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses., Pluvicto
OncoC4, Inc., Prostate Cancer Clinical Trials Consortium
Metastatic Castration-resistant Prostate Cancer
06/26
06/27
Brown, Robert
NCT05582681: HCV Test and Treat Utilizing Simplified HCV Patient Education

Recruiting
4
200
US
Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir, G/P
Weill Medical College of Cornell University, AbbVie
Hepatitis C
10/27
10/27
SPARTAN, NCT03938454: A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Completed
2
36
US
crizanlizumab, SEG101
Novartis Pharmaceuticals
Priapism
03/23
11/23
NX-DeTIL-0255-201, NCT05107739: A Study of DeTIL-0255 in Adults With Advanced Malignancies

Terminated
1
5
US
Drug Product De-TIL-0255
Nurix Therapeutics, Inc.
Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer
05/23
05/23
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
Alexander, H Richard
NCT01728051: Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver

No Longer Available
N/A
US
Melphalan, Percutaneous Hepatic Perfusion
Delcath Systems Inc.
Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma
 
 
Kim, Kevin
IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs

Recruiting
3
400
US
Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy
Replimune Inc.
Advanced Melanoma
01/29
08/34
CPMC17-MEL01, NCT03925350: Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Recruiting
2
41
US
Niraparib
California Pacific Medical Center Research Institute, Tesaro, Inc., Vanderbilt-Ingram Cancer Center, Huntsman Cancer Institute
Metastatic Melanoma
02/22
02/23
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recruiting
2
30
US
RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Replimune Inc., Roche Pharma AG
Hepatocellular Carcinoma
12/27
07/28
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
NCT00600496: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Checkmark P1 data
Mar 2012 - Mar 2012: P1 data
Active, not recruiting
1
140
US
AZD6244, ARRY-142886, Dacarbazine, Erlotinib, Docetaxel, Taxotere®, Temsirolimus
AstraZeneca
Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
08/10
12/24
NCT04735978: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Active, not recruiting
1
123
Europe, US
RP3, Nivolumab
Replimune Inc., Bristol-Myers Squibb
Advanced Solid Tumor
11/26
11/26
NCT05740293: Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment with the VisuMax SMILE Procedure

Active, not recruiting
N/A
171
US
VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism
Carl Zeiss Meditec, Inc.
Myopia, Astigmatism
09/24
03/25
Feigenberg, Steven
NCT05302817: Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI

Recruiting
1
20
US
Hyperpolarized xenon MRI
Xemed LLC, University of Pennsylvania
Carcinoma, Non-Small-Cell Lung
08/27
08/27
Shah, Nirav R
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
NCT06666491: An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

Recruiting
3
300
RoW
Tafenoquine, Primaquine, Chloroquine
GlaxoSmithKline
Malaria, Vivax
07/26
07/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT04738279: The CASCADE HF Soft Launch and Calibration Phase I and II

Completed
2/3
20
US
Non-Invasive Continuous Remote Patient Monitoring, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
NorthShore University HealthSystem, physIQ, Inc., Carnegie Mellon University, Northwestern University
Heart Failure
10/21
10/21
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed
2/3
125
Canada, US
LAU-7b, fenretinide, Placebo oral capsule
Laurent Pharmaceuticals Inc.
COVID-19 Disease
02/24
05/24
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Recruiting
2
123
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
NCT04283097: Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Recruiting
1
30
US
KPG-818, KPG-818 capsules
Kangpu Biopharmaceuticals, Ltd.
Hematological Malignancies
10/24
05/25
NCT05094206: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Terminated
1
4
US
0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells, 5x10^6 cells/kg CAR20.19.22 cells, Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
Medical College of Wisconsin, Miltenyi Biotec, Inc.
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia
01/24
01/24
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
120
US
Docirbrutinib, AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
SODA, NCT03771508: Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments

Recruiting
N/A
8000
US
Medtronic - MITG
Small Intestine Disease, Small Intestine Cancer, Small Intestinal Ulcer Bleeding, Small Intestine Obstruction, Small Intestine Adenocarcinoma, Small Intestine Polyp
12/25
12/25
Maluf, Daniel G
NCT04727788: Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection

Active, not recruiting
N/A
550
Europe, US
Verici Dx
Kidney Transplant Rejection
12/23
12/24
MAPLE, NCT04793360: Molecular Assessment and Profiling of Liver Transplant Recipients

Active, not recruiting
N/A
1500
US
LiverCare
CareDx
Liver Transplantation, Biomarkers
12/27
03/28
Rolfo, Christian
NCT05119933: A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Recruiting
1/2
55
US
YL-15293
Shanghai YingLi Pharmaceutical Co. Ltd., Yingli Pharma US, Inc
Advanced Solid Tumor
06/23
12/23
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
Jiang, Yixing
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
NCT05267899: A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

Recruiting
1
24
US
WGI-0301
Zhejiang Haichang Biotech Co., Ltd.
Advanced Solid Tumors
10/24
12/24
Gibson, C Michael
STAR-T, NCT04976530: Safe and Timely Antithrombotic Removal - Ticagrelor

Completed
N/A
140
Canada, US
DrugSorb-ATR system, Sorbent hemoperfusion system, Sham comparator
CytoSorbents, Inc
Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
08/23
08/23
STAR-D, NCT05093504: Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban

Terminated
N/A
9
US
Sham comparator, DrugSorb-ATR system, Sorbent hemoperfusion system
CytoSorbents, Inc
Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
01/24
01/24
Anderson, Lisa
i-LIVER, NCT06154278: Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

Recruiting
2
10
US
Imdusiran (AB-729)
University of Maryland, Baltimore, Arbutus Biopharma Corporation
Chronic Hepatitis B
12/26
07/27
ACTIVE2, NCT05269134: Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

Withdrawn
2
90
US
Bacteriophage, Placebo
Adaptive Phage Therapeutics, Inc.
Prosthetic Joint Infection
07/25
07/27
Cross, Raymond K
PROF, NCT05938465: Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects with an IPAA

Recruiting
1/2
50
US
EXE-346, Placebo
Exegi Pharma, LLC, The Emmes Company, LLC
Ileal Pouch
05/26
06/26
MONITOR, NCT06750731: Study of Efficacy and Adherence to Subcutaneous Vs. Intravenous Vedolizumab in Patients with Inflammatory Bowel Disease Using a Novel Remote ing Intervention

Not yet recruiting
N/A
200
US
Tappt
Mercy Medical Center, Takeda
Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
09/26
09/26
Graciano, Ana
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Recruiting
N/A
5000
Canada, US
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab
Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
09/26
09/27
Greenwald, Bruce
NCT06095804: Clinical Pilot Study of the Percutaneous Ultrasound Jejunostomy Procedure

Not yet recruiting
N/A
10
US
Percutaneous Ultrasound Jejunostomy
CoapTech, University of Maryland, Baltimore, University of Maryland Medical Center
Jejunostomy; Complications, Enteral and Supplement Feeds Adverse Reaction, Safety Issues
06/25
07/25
Griffith, Bartley
BOSTON-2, NCT03656926 / 2018-003205-25: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, Standard of Care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
03/24
03/24
BOSTON-1, NCT03657342 / 2018-003204-39: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, standard of care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
04/24
04/24
Shanholtz, Carl
RECOVER, NCT04629105: Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B

Active, not recruiting
1
70
US
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Longeveron Inc.
ARDS, Human, Covid19
06/24
07/25
Miller, Michael
ELSA-2, NCT05128955: Embolization of the Splenic Artery After Trauma

Recruiting
N/A
250
US
Splenic artery embolization with vascular embolic coils or plugs
Andrew J. Gunn, Penumbra Inc.
High-grade Splenic Injuries
04/25
04/25
Fasano, Alessio
NCT05636293: Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

Recruiting
2
30
US
Ritlecitinib, Placebo, Gluten
Massachusetts General Hospital, Pfizer
Celiac Disease
08/25
08/25
Lu, Wei
UplighTED, NCT06307626: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease.

Recruiting
3
108
Europe, Japan, US, RoW
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Thyroid Eye Disease
02/26
10/27
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders

Recruiting
2
162
RoW
BAT4406F Injection, BAT4406F Placebos
Bio-Thera Solutions
Optic Neuromyelitis Spectrum Disease
05/25
05/26
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting
2
70
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Intrahepatic Cholangiocarcinoma (ICC)
05/26
12/26
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Recruiting
1
40
RoW
NRT6003 Injection, Yttrium-90 carbon microspheres
Chengdu New Radiomedicine Technology Co. LTD.
Unresectable Hepatocellular Carcinoma
10/25
10/25
NCT05776121: Study of ZB001 in Chinese Patients With Thyroid Eye Disease

Active, not recruiting
1
17
RoW
ZB001 for injection
Zenas BioPharma (USA), LLC
Thyroid Eye Disease
10/24
10/24
NCT06047431: A Study of QL1706H in Patients With Advanced Solid Tumors

Not yet recruiting
1
150
NA
QL1706H
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumors
12/24
12/25
Tanaka, Kenichi
OPSTAHT, NCT03341156: Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation

Recruiting
3
60
US
Kcentra, prothrombin complex concentrate, Frozen Plasma Product, Human, Fresh Frozen Plasma
Kathirvel Subramaniam, University of Maryland, Baltimore, CSL Behring
Heart Disease End Stage, Heart Failure，Congestive
10/24
12/24
CRYPTICS, NCT04709705: DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery

Recruiting
2/3
200
US
Human platelets
Cellphire Therapeutics, Inc., U.S. Army Medical Research and Development Command
Cardiac Surgery
01/25
02/25
Gammie, James S
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting
N/A
150
US
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure, Inc.
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
06/24
06/26
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Mack, Michael
COAPT, NCT01626079: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The Trial) and CAS

Active, not recruiting
N/A
776
Canada, US
MitraClip System, MitraClip device, MitraClip
Abbott Medical Devices
Mitral Regurgitation, Mitral Valve Regurgitation, Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects, Heart Failure
03/19
07/24
NCT02675114: PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

Active, not recruiting
N/A
1000
Canada, Japan, US, RoW
SAVR, SAPIEN 3 THV
Edwards Lifesciences
Aortic Stenosis
11/20
12/29
STAR-T, NCT04976530: Safe and Timely Antithrombotic Removal - Ticagrelor

Completed
N/A
140
Canada, US
DrugSorb-ATR system, Sorbent hemoperfusion system, Sham comparator
CytoSorbents, Inc
Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
08/23
08/23
STAR-D, NCT05093504: Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban

Terminated
N/A
9
US
Sham comparator, DrugSorb-ATR system, Sorbent hemoperfusion system
CytoSorbents, Inc
Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
01/24
01/24
CLASP II TR, NCT04097145: Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

Recruiting
N/A
870
Canada, US
Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
12/27
12/31
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Cooper, Matthew
ProActive, NCT04091984: The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry

Active, not recruiting
N/A
5000
US
Prospera
Natera, Inc., University of Maryland
Kidney Transplant Rejection
10/26
10/27
Miller, Joseph
NCT04225598: Emergency Department-Initiated Buprenorphine Validation Network Trial

Completed
2
2000
US
CAM2038, Buprenorphine Sublingual Product
Yale University, National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, Harvard Medical School (HMS and HSDM), University of Pennsylvania, NYU Langone Health, Icahn School of Medicine at Mount Sinai, Alameda Health System, Weill Medical College of Cornell University, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
12/24
12/24
KOURAGE, NCT06374797: A Study of Auxora in Patients with AKI and Injurious Lung "Crosstalk"

Recruiting
2
150
US
Auxora, Placebo
CalciMedica, Inc.
Acute Kidney Injury
08/25
08/25
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
NCT06257628: MACE CDS Software Master Enrollment Protocol

Recruiting
N/A
5515
US
Index Event
Beckman Coulter, Inc.
Cardiac Events
11/24
04/25
MEDO, NCT04279431: Follow-up of MTBI Patients Discharged from the ED Using Standard Clinical Triage Including BrainScope One

Active, not recruiting
N/A
660
NA
EEG Recording, Neurocognitive Tests, Clinician Evaluation, 22-item CSI
BrainScope Company, Inc.
TBI (Traumatic Brain Injury), Concussion, Brain, MTBI - Mild Traumatic Brain Injury, Closed Head Injury
09/24
09/24
NCT06017622: Observational Study of THC Concentrations in Acute Cannabinoid Intoxication

Recruiting
N/A
120
US
Anebulo Pharmaceuticals
Acute Cannabinoid Intoxication
06/25
06/25
Shetty, Kirti
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
NCT03878550: Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma

Active, not recruiting
N/A
766
US, RoW
Glycotest, Inc.
Carcinoma, Hepatocellular, Cirrhosis, Liver
08/23
12/24
Khanna, Anna
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Recruiting
3
1683
US
Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Intracranial Arteriosclerosis, Stroke
05/28
05/28
FASTEST, NCT03496883: Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Recruiting
3
860
Europe, Canada, Japan, US
Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo
Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS)
Intracerebral Hemorrhage
01/28
01/28
Weir, Matthew R
PREFERRED-1, NCT05096195: PRevEnting FracturEs in REnal Disease 1

Active, not recruiting
4
60
Canada
Denosumab 60 mg/ml, Prolia, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate
Western University, Canada, ICES, Academic Medical Organization of Southwestern Ontario, Western University, The Kidney Foundation of Canada
Kidney Diseases, Dialysis; Complications, Fragility Fracture, Chronic Kidney Disease-Mineral and Bone Disorder
12/25
12/25
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT04658017: GARNETâ„¢ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection

Recruiting
N/A
15
US
GARNET device
Boa Biomedical, Inc., Avania
Bloodstream Infection
10/21
12/21
Lau, Christine
REFLECTION, NCT05205967: A Clinical Practice Learning Program for Galleri®

Recruiting
N/A
17000
US
MCED, SOC
GRAIL, LLC
Early Detection of Cancer, Cancer
06/25
08/26
NCT05780957: Multi-Cancer Early Detection (MCED) of Firefighters

Recruiting
N/A
2000
US
MCED
Vincere Cancer Center, Elypta
Cancer
12/24
12/30
Baddley, John
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24
Feller, Erika
PROACTIVE-HF, NCT04089059: IDE Trial Heart Failure NYHA Class III

Active, not recruiting
N/A
457
Europe, US
Cordella™ Pulmonary Artery Sensor System
Endotronix, Inc.
Heart Failure NYHA Class III
04/28
04/28
NCT05934487: PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

Recruiting
N/A
1650
US
Cordella™ Pulmonary Artery Sensor System
Endotronix, Inc.
Heart Failure NYHA Class II, Heart Failure NYHA Class III
09/27
09/29
Bromberg, Jonathan
NCT04803006: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Recruiting
2
18
US
TCD601
ITB-Med LLC
Kidney Transplantation
07/27
07/30
 

Download Options